Inhaled drug developer Avalyn Pharma has announced the appointments of Jill Denning as Senior VP, Clinical Development Operations, and Kimberley Cummings as Senior VP, Regulatory Affairs. Denning was most recently VP of Clinical Development at Kinevant Sciences and previously served in clinical development roles at a number of companies, including Altavant, Gilead, and Pharmasset. Cummings was most recently Senior VP of Regulatory Affairs and Clinical Development at Neurogastrx. Her previous experience includes stints at Levo Therapeutics and Cato Research.
Earlier this year, Avalyn announced that it had closed a $100 million Series D financing to support continued development of its inhaled drugs for the treatment of pulmonary fibrosis. The company’s pipeline consists of three products for the treatment of pulmonary fibrosis, including AP01 pirfenidone inhalation solution, AP02 nintedanib inhalation solution, and AP03 pirfenidone / nintedanib, which are delivered via PARI‘s eFlow nebulizer.
Avalyn CEO Lyn Baranowski commented, “We are excited to welcome Jill and Kimberley to our leadership team as we continue to advance our portfolio and prepare for key clinical and regulatory milestones. Jill brings extensive experience leading clinical programs from early pharmacology through late-stage development, and her ability to bridge scientific insight with operational execution will be crucial as we continue to progress our programs through the clinic. Kimberley adds deep regulatory affairs expertise, including in rare diseases and combination products, which will be invaluable as we navigate regulatory pathways for our programs. Together, these appointments position Avalyn to advance our lead programs through clinical development and one step closer to our goal of bringing new treatments to patients with life-threatening pulmonary diseases.”
Read the Avalyn Pharma press release
